Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss von de Bono, Johann S, De Giorgi, Ugo, Rodrigues, Daniel Nava, Massard, Christophe, Bracarda, Sergio, Font, Albert, Arranz Arija, Jose Angel, Shih, Kent C, Radavoi, George Daniel, Xu, Na, Chan, Wai Y, Ma, Han, Gendreau, Steven, Riisnaes, Ruth, Patel, Premal H, Maslyar, Daniel J, Jinga, Viorel

Volltext

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, plac... von Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, Kim, Sung-Bae, Lee, Keun Seok, Im, Seock-Ah, Espié, Marc, Wang, Hwei-Chung, Blau, Sibel, Dent, Rebecca, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Oliveira, Mafalda, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, Seigel, Leonard

Volltext

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer von Danila, Daniel C, Szmulewitz, Russell Z, Vaishampayan, Ulka, Higano, Celestia S, Baron, Ari D, Gilbert, Houston N, Brunstein, Flavia, Milojic-Blair, Marija, Wang, Bei, Kabbarah, Omar, Mamounas, Michael, Fine, Bernard M, Maslyar, Daniel J, Ungewickell, Alexander, Scher, Howard I

Volltext

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer von Weekes, Colin D, Lamberts, Laetitia E, Borad, Mitesh J, Voortman, Johannes, McWilliams, Robert R, Diamond, Jennifer R, de Vries, Elisabeth G E, Verheul, Henk M, Lieu, Christopher H, Kim, George P, Wang, Yulei, Scales, Suzie J, Samineni, Divya, Brunstein, Flavia, Choi, YounJeong, Maslyar, Daniel J, Colon-Otero, Gerardo

Volltext

Small-Molecule Antagonists of Myc/Max Dimerization Inhibit Myc-Induced Transformation of Chicken Embryo Fibroblasts von Berg, Thorsten, Cohen, Steven B., Desharnais, Joel, Sonderegger, Corinna, Maslyar, Daniel J., Goldberg, Joel, Boger, Dale L., Vogt, Peter K.

Volltext

Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia von Ward, Michael, Carter, Lawrence P., Huang, Julie Y., Maslyar, Daniel, Budda, Balasubrahmanyam, Paul, Robert, Rosenthal, Arnon

Volltext

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy... von Borrello, Ivan M., Levitsky, Hyam I., Stock, Wendy, Sher, Dorie, Qin, Lu, DeAngelo, Daniel J., Alyea, Edwin P., Stone, Richard M., Damon, Lloyd E., Linker, Charles A., Maslyar, Daniel J., Hege, Kristen M.

Volltext

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/me... von Dent, Rebecca, Im, Seock-Ah, Espie, Marc, Blau, Sibel, Tan, Antoinette R., Isakoff, Steven J., Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew, Kapp, Amy V., Chan, Wai Y., Singel, Stina M., Maslyar, Daniel J., Baselga, Jose, Kim, Sung-Bae

Volltext

Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches von Läubli, Heinz, Nalle, Sam C, Maslyar, Daniel

Volltext

Repeat IV and SC Dosing of the Anti-Sortilin Antibody AL101 (P7-6.007) von Park, Lovingly, Maslyar, Daniel, Ward, Michael, Yeh, Felix, Long, Hua, Kurnellas, Michael, Vadhavkar, Mayura, Budda, Balasubrahmanyam

Volltext

A First-in-Human Study of the Anti-Sortilin Antibody AL101 (P5-3.003) von Ward, Michael, Paul, Robert, Yeh, Felix, Long, Hua, Kurnellas, Michael, Silva, Amber, Ang, Emmanuel, Green, Jane, Maslyar, Daniel

Volltext

A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s disease (P5-3.002) von Maslyar, Daniel, Paul, Robert, Long, Hua, Rhinn, Herve, Tassi, Ilaria, Morrison, Glenn, Yeh, Felix, Schwabe, Tina, Ward, Michael

Volltext

AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors von Yang, Jingping, Deresa, Isaiah, Ho, Wei-Hsien, Long, Hua, Maslyar, Daniel, Rosenthal, Arnon, Liang, Spencer C, Pincetic, Andrew

Volltext

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer von Gerber, David E, Infante, Jeffrey R, Gordon, Michael S, Goldberg, Sarah B, Martín, Miguel, Felip, Enriqueta, Martinez Garcia, Maria, Schiller, Joan H, Spigel, David R, Cordova, Julie, Westcott, Valerie, Wang, Yulei, Shames, David S, Choi, YounJeong, Kahn, Robert, Dere, Randall C, Samineni, Divya, Xu, Jian, Lin, Kedan, Wood, Katie, Royer-Joo, Stephanie, Lemahieu, Vanessa, Schuth, Eva, Vaze, Anjali, Maslyar, Daniel, Humke, Eric W, Burris, 3rd, Howard A

Volltext

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer von Moore, Kathleen N., Birrer, Michael J., Marsters, Jim, Wang, Yulei, Choi, YounJeong, Royer-Joo, Stephanie, Lemahieu, Vanessa, Armstrong, Katy, Cordova, Julie, Samineni, Divya, Schuth, Eva, Vaze, Anjali, Maslyar, Daniel, Humke, Eric W., Hamilton, Erika P., Liu, Joyce F.

Volltext

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment von Lamberts, Laetitia E, Menke-van der Houven van Oordt, Catharina W, ter Weele, Eva J, Bensch, Frederike, Smeenk, Michiel M, Voortman, Johannes, Hoekstra, Otto S, Williams, Simon P, Fine, Bernard M, Maslyar, Daniel, de Jong, Johan R, Gietema, Jourik A, Schröder, Carolien P, Bongaerts, Alphons H H, Lub-de Hooge, Marjolijn N, Verheul, Henk M W, Sanabria Bohorquez, Sandra M, Glaudemans, Andor W J M, de Vries, Elisabeth G E

Volltext

Abstract 613: AL009 is a multi-Siglec inhibitor engineered to bind myeloid cells that enhances innate and adaptive immunity to cancer von Nalle, Sam, Lam, Helen, Barner, Cheryl, Long, Hua, Liang, Spencer, Rosenthal, Arnon, Maslyar, Daniel

Volltext

Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS elements von Comai, L, Moran, P, Maslyar, D

Volltext

NGS, RNA-Seq, TIL, and PTEN analyses in prostate cancer specimens from patients enrolled in the study of the Akt inhibitor ipatasertib (Ipat) combined with abiraterone acetate (AA) von Zhang, Liangxuan, Koeppen, Hartmut, Maslyar, Daniel J., Fillos, Dimitri, Xu, Na, Chan, Wai Y., Font Pous, Albert, Jinga, Viorel, Massard, Christophe, Bracarda, Sergio, Radavoi, George Daniel, De Giorgi, Ugo, Arranz Arija, Jose Angel, Riisnaes, Ruth, Nava Rodrigues, Daniel, De Bono, Johann S., Gendreau, Steven

Volltext

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cance... von Dent, Rebecca Alexandra, Kim, Sung-Bae, Im, Seock-Ah, Espie, Marc, Blau, Sibel, Tan, Antoinette R., Isakoff, Steven, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew, Kapp, Amy V., Chan, Wai Y., Singel, Stina M., Maslyar, Daniel J., Baselga, Jose

Volltext